TOP > 外国特許検索 > PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE, SCREENING METHOD THEREFOR, AND COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S DISEASE

PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE, SCREENING METHOD THEREFOR, AND COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S DISEASE NEW

外国特許コード F190009929
整理番号 (S2018-0247-N0)
掲載日 2019年10月24日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2018JP048471
国際公開番号 WO 2019132004
国際出願日 平成30年12月28日(2018.12.28)
国際公開日 令和元年7月4日(2019.7.4)
優先権データ
  • 特願2017-254887 (2017.12.28) JP
発明の名称 (英語) PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE, SCREENING METHOD THEREFOR, AND COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S DISEASE NEW
発明の概要(英語) A prophylactic agent or therapeutic agent for Alzheimer's disease characterized by containing a GM1 gangliosidosis prophylactic agent or therapeutic agent as an active ingredient. A screening method for prophylactic agents or therapeutic agents for Alzheimer's disease characterized by involving the use of a GM1 gangliosidosis prophylactic agent or therapeutic agent.
従来技術、競合技術の概要(英語) BACKGROUND ART
Alzheimer's disease (hereinafter, also referred to as' AD '.) Is, up to 60-70% of the dementia, most countries and the monetary cost which has a high rate. As a mechanism of AD the onset of disease, amyloid β (hereinafter, also referred to as' A β '.) Increases due to failure or degradation of the yield, A β amyloid cascade hypothesis as the start point stored in the most supported.
A β is, a small molecular weight of about 4kD amino acids of 38-43 protein, amyloid precursor protein (APP) is produced from the cut out by beta-secretase. A β of the major molecular species, due to a difference in the number of amino acids, Aβ40 and Aβ42 exist. Of these, is Aβ42, has a high cohesion, having a stronger known pathogenic.
To the AD in the development of therapeutic agents, various efforts have been made (see Non-Patent Document 1.). For example, in non-patent document 1, human iPS cells differentiated from the brain and nerve cells expressing the marker before using the method for screening of anti-A β respectively.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
  • 発明者(英語)
  • ERA Takumi
  • KAJIHARA Ryutaro
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」まで直接ご連絡ください。

PAGE TOP

close
close
close
close
close
close